The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LEGEND: A phase 1/2 study of detalimogene voraplasmid (EG-70), an intravesical monotherapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC).
 
Jen-Jane Liu
Consulting or Advisory Role - enGene
Research Funding - enGene; Merck
Expert Testimony - GlaxoSmithKline
 
Raj Satkunasivam
Consulting or Advisory Role - Pfizer
Research Funding - Anchiano; BMS Brazil; CG Oncology; Colmmune; enGene; Janssen; Merck; Pfizer; Photocure; Protara Therapeutics; QED Therapeutics; UroGen pharma
Other Relationship - I was specifically contracted and paid to provide expertise and support for the NMIBC patient preference study
 
Rian Dickstein
Employment - Chesapeake Urology
Honoraria - UroGPO
Consulting or Advisory Role - CG Oncology; Ferring; Johnson & Johnson/Janssen; Olympus; Photocure; Urogen pharma
Speakers' Bureau - Ferring; Urogen pharma
 
Shreyas Joshi
Consulting or Advisory Role - Blue Earth Diagnostics; CG Oncology; enGene
 
Sam Chang
Honoraria - CG Oncology; enGene; Lantheus Medical Imaging; Merck Sharp & Dohme; Pfizer; Photocure; UroGen pharma
Consulting or Advisory Role - CG Oncology; enGene; Janssen Biotech; Lantheus Medical Imaging; Merck; Pfizer; Photocure
Research Funding - CG Oncology (Inst); ImmunityBio (Inst); Johnson & Johnson (Inst); UroGen pharma (Inst)
Travel, Accommodations, Expenses - UroGen pharma
 
Gautam Jayram
Honoraria - BMS Brazil; enGene; Ferring; J/J; Merck; Pfizer; Specialty Networks; Telix Pharmaceuticals
Consulting or Advisory Role - enGene; Ferring; J/J; Merck; Pfizer; Specialty Networks; Telix Pharmaceuticals
Speakers' Bureau - Bayer; Ferring; J/J; Merck; Photocure
Research Funding - AstraZeneca; Aura Biosciences; CG Oncology; enGene; Ferring; J/J; Merck; Protara Therapeutics; Theralase; UroGen pharma
 
Neal Shore
Employment - GenesisCare
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
 
Yair Lotan
Stock and Other Ownership Interests - CAPs medical; Nanorobotics; Phinomics; trigone pharma; Uroviu; vesica health; Vessi Medical; Virtuoso Therapeutics
Consulting or Advisory Role - Abbvie; Ambu; AstraZeneca; Aura Biosciences; BMS; caps medical; Cleveland Diagnostics; Convergent Genomics; Fergene; ImmunityBio; Janssen; Merck; Nanogen Biopharmaceutical; Nanorobotics; nrx pharmaceuticals; Nucleix; pacific edge; phinomics; Photocure; Seagen; Stimit; trigone pharma; Urogen pharma; uroviu; verity pharmaceuticals; Vessi Medical; virtuoso surgical; Xcures
Research Funding - Abbott Molecular (Inst); Augmenix; BioCancell (Inst); Cepheid; Cepheid (Inst); GenomeDx (Inst); MDxHealth (Inst); pacific edge; pacific edge (Inst); Photocure (Inst); storz (Inst)
 
Anne Schuckman
Honoraria - CG Oncology; EnGene; pacific edge; Photocure
Consulting or Advisory Role - Fergene; Gerson Lehrman Group; Pacific Edge Biotechnology; Pacific Edge Biotechnology; Photocure
Speakers' Bureau - Photocure
 
Raj Pruthi
Employment - enGene Inc
 
Anthony Cheung
Employment - enGene Inc
Stock and Other Ownership Interests - enGene Inc
 
Katherine Chan
Employment - enGene Inc; UNC School of Medicine
 
Christine Tosone
Employment - enGene Inc
 
Scott Johnson
No Relationships to Disclose
 
Vignesh Packiam
Honoraria - enGene; Ferring; Johnson & Johnson
Consulting or Advisory Role - Photocure; Valar Labs
Speakers' Bureau - UroGen pharma; Veracyte
 
Christine Ibilibor
No Relationships to Disclose
 
Wassim Kassouf
Consulting or Advisory Role - AstraZeneca; BMS; Ferring; Janssen; Merck; Pfizer/EMD Serono; Photocure; Roche; Seagen
 
Ashish Kamat
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Aspira Women's Health (I); Astellas Pharma; AstraZeneca; CG Oncology; Cystotech; enGene; Ferring; Genentech; GlaxoSmithKline (I); ImmunityBio; Imvax; Janssen; Merck; Nonagen Bioscience; Pfizer; Seagen; Theralase; Valar Labs; Vivet Therapeutics
Research Funding - Arquer Diagnostics (Inst); enGene (Inst); FKD Therapies (Inst); Patient-Centered Outcomes Research Institute (PCORI) (Inst); Photocure (Inst); Seagen (Inst); SWOG (Inst)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - Bladder Cancer Advocacy Network; European Urology Oncology; International Bladder Cancer Group (IBCG); Journal of Urology; UroToday
 
John Taylor
Consulting or Advisory Role - enGene
Other Relationship - Photocure
 
Gary Steinberg
Stock and Other Ownership Interests - CG Oncology; enGene; Epivax Therapeutics
Honoraria - Aduro Biotech; AstraZeneca; Bristol-Myers Squibb; CG Oncology; enGene; Epivax Oncology; fergene; Ferring; Fidia Farmaceutici S. p. A.; FKD Therapies; Janssen Oncology; MDxHealth; Merck; Pfizer; Photocure; Roche/Genentech; Seagen; Sesen Bio; Urogen pharma
Consulting or Advisory Role - Asieris Pharmaceuticals; AstraZeneca; Aura Biosciences; Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; Imvax; MDxHealth; Merck; NanOlogy; Natera; Nonagen Bioscience; photocure; Roche/Genentech; Taris BioMedical; Verity Pharmaceuticals